Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL929913 | 0.91 | LMNA (0.37) | HTR6KCNH2LMNACYP2C9 | |
| Hydrochloric Acid SCHEMBL14880059 | 0.88 | LMNA (0.36) | HTR6KCNH2LMNACYP2C9 | |
| SCHEMBL701588 | 0.85 | MAPK1 (0.46) | HTR6MAPK1LMNACYP2C9 | |
| Hydrochloric Acid SCHEMBL274610 | 0.83 | MAPK1 (0.44) | HTR6MAPK1LMNACYP2C9 | |
| SCHEMBL1449366 | 0.80 | HTR6 (0.43) | HTR6MAPK1LMNACYP2C9 | |
| SCHEMBL10690019 | 0.79 | — | — | |
| SCHEMBL9595459 | 0.78 | LMNA (0.42) | MAPK1LMNACYP2C9 | |
| SCHEMBL14320158 | 0.77 | MAPK1 (0.57) | MAPK1LMNACYP2C9 | |
| SCHEMBL410993 | 0.77 | MAPK1 (0.57) | MAPK1LMNACYP2C9 | |
| Pyrrolidine SCHEMBL21806662 | 0.76 | MAPK1 (0.43) | HTR6MAPK1LMNACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7994156-B2 | Carboxylic acid 4-phenylazo-phenyl ester derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | NEUROSEARCH A/S (DK) | 2011-08-09 | — | — | US | disclosed |
| US-20100311699-A1 | NOVEL CARBOXYLIC ACID 4-PHENYLAZO-PHENYL ESTER DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2010-12-09 | — | — | US | disclosed |
| US-7060699-B2 | Aryl and heteroaryl diazabicycloalkanes, their preparation and use | NEUROSEARCH A/S (DK) | 2006-06-13 | — | — | US | disclosed |
| EP-1301514-B1 | ARYL AND HETEROARYL DIAZABICYCLOALKANES, THEIR PREPARATION AND USE | NEUROSEARCH AS (DK) | 2005-01-26 | — | — | EP | disclosed |
| CN-1185233-C | Aryl and heteroaryl diazabicycloalkanes, their preparation and use | NEUROSEARCH AS (DK) | 2005-01-19 | — | — | CN | disclosed |
| EP-1177196-B1 | HETEROARYL DIAZABICYCLOALKANES, THEIR PREPARATION AND USE | NEUROSEARCH AS (DK) | 2004-03-10 | — | — | EP | disclosed |
| US-20030176416-A1 | Aryl and heteroaryl diazabicycloalkanes, their preparation and use | NEUROSEARCH A/S (DK) | 2003-09-18 | — | — | US | disclosed |
| CN-1440411-A | Aryl and heteroaryl diazabicycloalkanes, their preparation and use | NEUROSEARCH AS (DK) | 2003-09-03 | — | — | CN | disclosed |
| US-6552012-B2 | 3-(6-Chloro-(3-pyridazinyl))-9-methyl-3,9-diazabicyclo(4.2.1)-nonane, for example; Alzheimer's disease, Parkinson's disease, memory dysfunction, smoking cessation, drug abuse, drug dependence; cholinergic ligands | NEUROSEARCH A/S (DK) | 2003-04-22 | — | — | US | disclosed |
| EP-1301514-A1 | ARYL AND HETEROARYL DIAZABICYCLOALKANES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 2003-04-16 | — | — | EP | disclosed |
| US-20020037893-A1 | Heteroaryl diazabicycloalkanes, their preparation and use | ANIONA APS (DK) | 2002-03-28 | — | — | US | disclosed |
| EP-1177196-A1 | HETEROARYL DIAZABICYCLOALKANES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 2002-02-06 | — | — | EP | disclosed |
| WO-2002002564-A1 | ARYL AND HETEROARYL DIAZABICYCLOALKANES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 2002-01-10 | — | — | WO | disclosed |
| WO-2000066586-A1 | HETEROARYL DIAZABICYCLOALKANES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176416-A1 | Aryl and heteroaryl diazabicycloalkanes, their preparation and use | CHRNA7, CHRNA5, CHRNA2 | HTR6 87/4885MAPK1 1108/4885KCNH2 733/4885 |
| US-20100311699-A1 | NOVEL CARBOXYLIC ACID 4-PHENYLAZO-PHENYL ESTER DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | SLC18A2, SLC6A2, SLC18A3 | HTR6 86/4885MAPK1 3093/4885KCNH2 1957/4885 |
| US-20020037893-A1 | Heteroaryl diazabicycloalkanes, their preparation and use | CHRNA5, CHRNA7, CHRNA2 | HTR6 804/4885MAPK1 810/4885KCNH2 906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.